Rivastigmine in Alzheimer’s Disease and Parkinson’s Disease Dementia

Abstract

Rivastigmine treatment is associated with significant improvements on the cognitive subscale of the Alzheimer’s Disease Assessment Scale (ADAS-cog) in patients with mild-to-moderate Alzheimer’s disease (AD) and Parkinson’s disease dementia (PDD). Both AD and PDD are purported to have different profiles of cognitive impairment, which may respond differentially to rivastigmine treatment. This was a retrospective analysis of 3 randomized, double-blind, rivastigmine trial databases (Investigation of transDermal Exelon in ALzheimer's disease [IDEAL; AD], EXelon in PaRkinson's disEaSe dementia Study [EXPRESS; PDD], and Alzheimer's Disease with ENA 713 [ADENA; AD]). Factor analyses of the 11 baseline ADAS-cog items derived the same factors in the 2 diseases, that is, “memory” and “language”. Rivastigmine-treated AD and PDD patients showed significant improvements ( P < .0001 versus placebo) on both factors. For both AD and PDD, rivastigmine had a numerically greater effect on memory than language. Treatment effect sizes were numerically greater in PDD compared with AD. Rivastigmine treatment is associated with improvement in memory and language in AD and PDD. The numerically greater response in PDD is consistent with greater cholinergic deficits in this disease state.